Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04338282

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type Clinical Trial

Official title:
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma: a Single Arm, Single Center, Open Label, Phase 2 Trial

Clinical Trial Summary

For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to suffer from disease relapse. Thus, this study aims to evaluate the role of maintenance with anti-PD-1 antibody.

Clinical Trial Description

For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to suffer from disease relapse. The investigators previously reported one-year progression free survival rate of 22.2% for patients with positive plasma EBV-DNA at the end of treatments. Recently, anti-PD-1 antibody has been shown to be highly effective in the treatment of NK/T-cell lymphoma. Thus, this study aims to evaluate the role of maintenance with anti-PD-1 antibody for patients with positive plasma EBV-DNA at the end of treatments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04338282
Study type Interventional
Source Beijing Tongren Hospital
Contact LIANG WANG, M.D.
Phone +8615013009093
Email wangliangtrhos@126.com
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2020
Completion date May 31, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04509466 - Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL Phase 1/Phase 2
Not yet recruiting NCT04676789 - Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL Phase 2
Active, not recruiting NCT01991158 - GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma Phase 2
Active, not recruiting NCT03363555 - SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma Phase 2
Recruiting NCT04405375 - GPED Regimen for Relapsed/Refractory or Advanced ENKTCL Phase 2
Recruiting NCT02742727 - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT02631239 - MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Phase 3
Recruiting NCT01667302 - Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Phase 2
Terminated NCT01667289 - Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma Phase 2
Active, not recruiting NCT04414163 - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Phase 2
Recruiting NCT05978141 - A Registry for People With T-cell Lymphoma
Completed NCT02386813 - International Extranodal NK/T-cell Lymphoma Project N/A
Recruiting NCT01921790 - Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2